catalym
Posted by catalym
November 8, 2023
November 8, 2023

ESMO I-O Congress 2023

Dec 6 - Dec 8, 2023

Read More
catalym
Posted by catalym
November 8, 2023
November 8, 2023

JPM 2024

Jan 8 -Jan 11, 2024

Read More
catalym
Posted by catalym
October 27, 2023
October 27, 2023

12P Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells

Schuberth-Wagner, C., Giese, I., Kist, M., Vashist, N., Genßler, S., Haack, B.,...

Read More
catalym
Posted by catalym
October 26, 2023
catalym
Posted by catalym
October 16, 2023
catalym
Posted by catalym
October 12, 2023
October 12, 2023

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm  /  Drug Target...

Read More
catalym
Posted by catalym
October 12, 2023
October 12, 2023

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick...

Read More
catalym
Posted by catalym
July 20, 2023
July 20, 2023

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...

Read More
catalym
Posted by catalym
June 5, 2023
June 5, 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...

Read More
catalym
Posted by catalym
May 25, 2023
May 25, 2023

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...

Read More
WordPress Cookie Notice by Real Cookie Banner